Perry Karsen brings decades of successful executive leadership and board experience to his role as an Executive Chair of Autobahn Labs and Venture Partner at Samsara BioCapital. Karsen currently serves as a member of the Boards for Intellia Therapeutics, the privately held company E-Scape, the Gladstone Foundation and the Sonoma Land Trust. He also is chairman of the Board of Directors for Jounce Therapeutics. In 2020, Karsen was appointed as a Fellow in the Stanford University Distinguished Careers Institute. He also has been a board member and a member of the Executive Committee of the Biotechnology Innovation Organization (BIO) and the Alliance for Regenerative Medicine (ARM).
Karsen served as the Chief Executive Officer of the Celgene Cellular Therapeutics division (CCT) of Celgene Corporation, a global biopharmaceutical company. Karsen was also President and Chief Executive Officer of Pearl Therapeutics, Inc., a privately held biotechnology company subsequently acquired by AstraZeneca plc. Karsen also has held executive positions at Human Genome Sciences, Inc., a biopharmaceutical company subsequently acquired by GlaxoSmithKline, Bristol-Myers Squibb Co., Genentech, Inc. (a member of the Roche Group) and Abbott Laboratories. He previously served as a general partner at Pequot Ventures, a venture capital firm.
Karsen earned an MIM from Northwestern University’s Kellogg Graduate School of Management, an M.A. in the teaching of Biology from Duke University and a B.S. in Biological Sciences from the University of Illinois, Urbana-Champaign.